Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," ...

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results , but sales were flat year on year at $3.75 billion. Its ...

Over the last few months, as Len just mentioned, we have delivered multiple important data readouts, showcasing the strength of our robust pipeline and the potential to drive future growth with ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

After news broke last weekend that President Donald Trump tested positive for COVID-19, Regeneron CEO Leonard Schleifer ’73 was once again thrust into the spotlight, running the biotech company ...

“I expect this to substantially increase the sales,” Regeneron CEO Leonard Schleifer, MD, PhD, told Reuters. 4. Express Scripts will share a portion of the rebates it receives for Praluent with ...

(Reuters) -Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from ...

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its ...

The CEOs of the 14 biotech and pharmaceutical companies included in Standard & Poor’s 500 that held their roles for the full 2015 fiscal year earned median compensation packages of $18.5 million for ...

Only 24 CEOs on the 2025 Fortune 500 list are founders or co-founders of the companies they lead. That amounts to just 4.8% of the index. Yet this small group commands outsized influence. Collectively ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...